GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) — Stock Price
GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) is currently trading at Rs2601.00 INR, up 0.05% today. Over the past 52 weeks, shares have ranged between Rs2103.20 and Rs2863.80. This page tracks GlaxoSmithKline Pharmaceuticals Limited's live share price on the NSE exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see GlaxoSmithKline Pharmaceuticals Limited market capitalisation.
GlaxoSmithKline Pharmaceuticals Limited (GLAXO) Stock Price Chart — Daily History & Trading Volume
The chart below tracks GlaxoSmithKline Pharmaceuticals Limited's daily closing share price and trading volume on the NSE exchange over the past year, giving a clear view of recent price momentum and liquidity.
GlaxoSmithKline Pharmaceuticals Limited Income Statement — Revenue, Profit & Earnings by Year
GlaxoSmithKline Pharmaceuticals Limited's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | Rs37.49 Billion | Rs34.54 Billion | Rs32.52 Billion | Rs32.78 Billion | Rs29.26 Billion |
| Cost of Revenue | Rs14.14 Billion | Rs13.55 Billion | Rs13.04 Billion | Rs13.78 Billion | Rs12.82 Billion |
| Gross Profit | Rs23.35 Billion | Rs20.99 Billion | Rs19.48 Billion | Rs19.00 Billion | Rs16.43 Billion |
| Research & Development | Rs26.12 Million | Rs25.44 Million | Rs19.10 Million | Rs18.29 Million | Rs18.07 Million |
| SG&A | Rs5.82 Billion | Rs6.26 Billion | Rs5.97 Billion | Rs6.12 Billion | Rs6.18 Billion |
| Total Operating Expenses | Rs7.04 Billion | Rs7.38 Billion | Rs7.08 Billion | Rs7.42 Billion | Rs6.88 Billion |
| Operating Income | Rs16.31 Billion | Rs13.60 Billion | Rs12.39 Billion | Rs11.58 Billion | Rs9.56 Billion |
| EBITDA | Rs11.53 Billion | Rs8.81 Billion | Rs7.88 Billion | Rs7.43 Billion | Rs5.73 Billion |
| EBIT | Rs11.14 Billion | Rs8.39 Billion | Rs7.48 Billion | Rs6.99 Billion | Rs5.20 Billion |
| Interest Expense | Rs11.79 Million | Rs17.99 Million | Rs18.10 Million | Rs19.96 Million | Rs35.31 Million |
| Income Before Tax | Rs12.60 Billion | Rs8.16 Billion | Rs8.36 Billion | Rs7.79 Billion | Rs4.54 Billion |
| Income Tax Expense | Rs3.32 Billion | Rs2.26 Billion | Rs2.29 Billion | Rs3.98 Billion | Rs1.67 Billion |
| Net Income | Rs9.28 Billion | Rs5.90 Billion | Rs6.11 Billion | Rs16.95 Billion | Rs3.58 Billion |
GlaxoSmithKline Pharmaceuticals Limited Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes GlaxoSmithKline Pharmaceuticals Limited's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | Rs41.08 Billion | Rs35.57 Billion | Rs33.27 Billion | Rs46.33 Billion | Rs31.13 Billion |
| Total Current Assets | Rs34.10 Billion | Rs27.98 Billion | Rs24.94 Billion | Rs37.08 Billion | Rs22.03 Billion |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | Rs19.59 Billion | Rs17.93 Billion | Rs16.19 Billion | Rs25.45 Billion | Rs7.32 Billion |
| Net Receivables | Rs3.61 Billion | Rs3.50 Billion | Rs3.30 Billion | Rs2.05 Billion | Rs2.41 Billion |
| Inventory | Rs4.82 Billion | Rs5.25 Billion | Rs4.60 Billion | Rs5.35 Billion | Rs5.47 Billion |
| Property, Plant & Equipment | — | — | — | Rs3.25 Billion | Rs3.54 Billion |
| Goodwill | — | — | Rs-8.00K | — | — |
| Total Liabilities | Rs21.57 Billion | Rs17.79 Billion | Rs15.85 Billion | Rs19.70 Billion | Rs16.14 Billion |
| Total Current Liabilities | Rs19.05 Billion | Rs15.25 Billion | Rs13.26 Billion | Rs16.98 Billion | Rs13.55 Billion |
| Long-term Debt | — | — | — | — | Rs0.00 |
| Net Debt | Rs-13.94 Billion | Rs-455.06 Million | Rs-194.00 Million | Rs-2.66 Billion | Rs-3.71 Billion |
| Total Stockholder Equity | Rs19.51 Billion | Rs17.78 Billion | Rs17.41 Billion | Rs26.63 Billion | Rs14.78 Billion |
| Retained Earnings | Rs10.59 Billion | Rs8.76 Billion | Rs15.92 Billion | Rs17.43 Billion | Rs5.56 Billion |
GlaxoSmithKline Pharmaceuticals Limited Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how GlaxoSmithKline Pharmaceuticals Limited generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | Rs12.90 Billion | Rs5.82 Billion | Rs4.84 Billion | Rs8.11 Billion | Rs5.78 Billion |
| Capital Expenditures | Rs230.20 Million | Rs312.21 Million | Rs440.40 Million | Rs346.41 Million | Rs442.27 Million |
| Free Cash Flow | Rs12.67 Billion | Rs5.51 Billion | Rs4.40 Billion | Rs7.76 Billion | Rs5.34 Billion |
| Investing Cash Flow | Rs-458.10 Million | Rs87.12 Million | Rs8.08 Billion | Rs-4.06 Billion | Rs4.19 Billion |
| Financing Cash Flow | Rs-7.69 Billion | Rs-5.61 Billion | Rs-15.43 Billion | Rs-5.24 Billion | Rs-6.96 Billion |
| Dividends Paid | Rs-7.49 Billion | Rs-5.42 Billion | Rs15.26 Billion | Rs5.07 Billion | Rs6.78 Billion |
| Stock-Based Compensation | — | Rs113.97 Million | Rs25.33 Million | Rs65.45 Million | Rs128.51 Million |
| Depreciation | Rs667.90 Million | Rs696.80 Million | Rs657.70 Million | Rs681.86 Million | Rs792.84 Million |
| Change in Cash | Rs4.75 Billion | Rs292.30 Million | Rs-2.51 Billion | Rs-1.19 Billion | Rs3.00 Billion |
GlaxoSmithKline Pharmaceuticals Limited Earnings History — EPS Actual vs. Analyst Estimates
Track GlaxoSmithKline Pharmaceuticals Limited's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| May 11, 2026 | — | — | — |
| Feb 12, 2026 | — | — | — |
| Oct 27, 2025 | — | — | — |
| Jul 31, 2025 | — | — | — |
| May 13, 2025 | — | — | — |
| Feb 10, 2025 | — | — | — |
| Feb 12, 2024 | 9.89 | 11.29 | -12.40% |
| Nov 09, 2023 | 12.84 | — | — |